Maas, M.; Hilsendecker, A.; Pertoll, A.; Stühler, V.; Walz, S.; Rausch, S.; Stenzl, A.; Tsaur, I.; Hennenlotter, J.; Aufderklamm, S.
PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy. Cancers 2024, 16, 1356.
https://doi.org/10.3390/cancers16071356
AMA Style
Maas M, Hilsendecker A, Pertoll A, Stühler V, Walz S, Rausch S, Stenzl A, Tsaur I, Hennenlotter J, Aufderklamm S.
PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy. Cancers. 2024; 16(7):1356.
https://doi.org/10.3390/cancers16071356
Chicago/Turabian Style
Maas, Moritz, Andreas Hilsendecker, Alexandra Pertoll, Viktoria Stühler, Simon Walz, Steffen Rausch, Arnulf Stenzl, Igor Tsaur, Jörg Hennenlotter, and Stefan Aufderklamm.
2024. "PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy" Cancers 16, no. 7: 1356.
https://doi.org/10.3390/cancers16071356
APA Style
Maas, M., Hilsendecker, A., Pertoll, A., Stühler, V., Walz, S., Rausch, S., Stenzl, A., Tsaur, I., Hennenlotter, J., & Aufderklamm, S.
(2024). PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy. Cancers, 16(7), 1356.
https://doi.org/10.3390/cancers16071356
